LabCorp
LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Alert:
LabCorp COVID-19 Antibody Testing Available Nationwide Learn more >>>
Expected Turnaround Time
3 - 7 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
|
3 - 7 days |
|
3 - 7 days |
Related Documents
Specimen Requirements
Specimen
Plasma, frozen
|
Plasma, frozen |
|
Plasma, frozen |
Volume
0.5 mL
|
0.5 mL |
|
0.5 mL |
Minimum Volume
0.1 mL (Note: This volume does not allow for repeat testing)
Container
Green-top (sodium heparin) tube
|
Green-top (sodium heparin) tube |
|
Green-top (sodium heparin) tube |
Collection
Transfer plasma to a plastic transport tube and freeze. To avoid delays in turnaround time when requesting multiple tests on frozen specimens, please submit separate frozen specimens for each test requested.
|
Transfer plasma to a plastic transport tube and freeze. To avoid delays in turnaround time when requesting multiple tests on frozen specimens, please submit separate frozen specimens for each test requested. |
|
Transfer plasma to a plastic transport tube and freeze. To avoid delays in turnaround time when requesting multiple tests on frozen specimens, please submit separate frozen specimens for each test requested. |
Storage Instructions
Freeze
|
Freeze |
|
Freeze |
Causes for Rejection
Specimen thawed or not frozen; gross hemolysis; specimen type other than frozen plasma
|
Specimen thawed or not frozen; gross hemolysis; specimen type other than frozen plasma |
|
Specimen thawed or not frozen; gross hemolysis; specimen type other than frozen plasma |
Test Details
Use
Used in the diagnosis and monitoring of inherited disorders of fatty acid oxidation and organic acidurias. May be used as a follow-up test to some abnormal newborn screen results.
|
Used in the diagnosis and monitoring of inherited disorders of fatty acid oxidation and organic acidurias. May be used as a follow-up test to some abnormal newborn screen results. |
|
Used in the diagnosis and monitoring of inherited disorders of fatty acid oxidation and organic acidurias. May be used as a follow-up test to some abnormal newborn screen results. |
Limitations
False-negative results can occur with acylcarnitine profiling, especially when the patient is carnitine deficient, is affected with a milder variant of a disorder, or when clinical condition or dietary supplementation causes secondary changes to the profile. Results of acylcarnitine profiling should be interpreted in the context of clinical presentation as well as other laboratory tests, which may include urine organic acid analysis and molecular testing.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
|
False-negative results can occur with acylcarnitine profiling, especially when the patient is carnitine deficient, is affected with a milder variant of a disorder, or when clinical condition or dietary supplementation causes secondary changes to the profile. Results of acylcarnitine profiling should be interpreted in the context of clinical presentation as well as other laboratory tests, which may include urine organic acid analysis and molecular testing. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). |
|
False-negative results can occur with acylcarnitine profiling, especially when the patient is carnitine deficient, is affected with a milder variant of a disorder, or when clinical condition or dietary supplementation causes secondary changes to the profile. Results of acylcarnitine profiling should be interpreted in the context of clinical presentation as well as other laboratory tests, which may include urine organic acid analysis and molecular testing. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). |
Methodology
Flow injection/tandem mass spectrometry
|
Flow injection/tandem mass spectrometry |
|
Flow injection/tandem mass spectrometry |
References
Applied Biosystems. Chemoview Instructions. March 15, 2005.
Bennett M. Laboratory Medicine Practice Guidelines−Follow-up Testing for Metabolic Diseases Identified by Expanded Newborn Screening Using Tandem Mass Spectrometry. Washington DC: AACC Press;2009.
Rinaldo P, Cowan TM, Matern D. Acylcarnitine profile analysis. Genet Med. 2008 Feb; 10(2):151-156.18281923
|
Applied Biosystems. Chemoview Instructions. March 15, 2005. Bennett M. Laboratory Medicine Practice Guidelines−Follow-up Testing for Metabolic Diseases Identified by Expanded Newborn Screening Using Tandem Mass Spectrometry. Washington DC: AACC Press;2009. Rinaldo P, Cowan TM, Matern D. Acylcarnitine profile analysis. Genet Med. 2008 Feb; 10(2):151-156.18281923 |
|
Applied Biosystems. Chemoview Instructions. March 15, 2005. Bennett M. Laboratory Medicine Practice Guidelines−Follow-up Testing for Metabolic Diseases Identified by Expanded Newborn Screening Using Tandem Mass Spectrometry. Washington DC: AACC Press;2009. Rinaldo P, Cowan TM, Matern D. Acylcarnitine profile analysis. Genet Med. 2008 Feb; 10(2):151-156.18281923 |
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 070228 | Acylcarnitine Profile, Plasma | 070081 | C2 | umol/L | 30191-1 | |
| 070228 | Acylcarnitine Profile, Plasma | 070040 | C3 | umol/L | 30551-6 | |
| 070228 | Acylcarnitine Profile, Plasma | 070041 | C3-Dicarboxylic | umol/L | 55940-1 | |
| 070228 | Acylcarnitine Profile, Plasma | 070042 | C4 | umol/L | 51413-3 | |
| 070228 | Acylcarnitine Profile, Plasma | 070043 | C4-Hydroxy | umol/L | 39000-5 | |
| 070228 | Acylcarnitine Profile, Plasma | 070119 | C4-Dicarboxylic | umol/L | 39010-4 | |
| 070228 | Acylcarnitine Profile, Plasma | 070044 | C5 | umol/L | 30531-8 | |
| 070228 | Acylcarnitine Profile, Plasma | 070048 | C5:1 | umol/L | 69573-4 | |
| 070228 | Acylcarnitine Profile, Plasma | 070049 | C5-Hydroxy | umol/L | 51412-5 | |
| 070228 | Acylcarnitine Profile, Plasma | 070051 | C5-Dicarboxylic | umol/L | 30349-5 | |
| 070228 | Acylcarnitine Profile, Plasma | 070057 | C6 | umol/L | 30358-6 | |
| 070228 | Acylcarnitine Profile, Plasma | 070058 | C8 | umol/L | 30540-9 | |
| 070228 | Acylcarnitine Profile, Plasma | 070059 | C10 | umol/L | 30327-1 | |
| 070228 | Acylcarnitine Profile, Plasma | 070061 | C10:1 | umol/L | 30328-9 | |
| 070228 | Acylcarnitine Profile, Plasma | 070062 | C10:2 | umol/L | 53471-9 | |
| 070228 | Acylcarnitine Profile, Plasma | 070063 | C12 | umol/L | 30331-3 | |
| 070228 | Acylcarnitine Profile, Plasma | 070064 | C14 | umol/L | 30565-6 | |
| 070228 | Acylcarnitine Profile, Plasma | 070065 | C14:1 | umol/L | 30566-4 | |
| 070228 | Acylcarnitine Profile, Plasma | 070066 | C14:2 | umol/L | 30564-9 | |
| 070228 | Acylcarnitine Profile, Plasma | 070067 | C14-Hydroxy | umol/L | 30238-0 | |
| 070228 | Acylcarnitine Profile, Plasma | 070068 | C16 | umol/L | 30356-0 | |
| 070228 | Acylcarnitine Profile, Plasma | 070069 | C16:1 | umol/L | 30357-8 | |
| 070228 | Acylcarnitine Profile, Plasma | 070070 | C16:1-Hydroxy | umol/L | 30235-6 | |
| 070228 | Acylcarnitine Profile, Plasma | 070071 | C16-Hydroxy | umol/L | 30234-9 | |
| 070228 | Acylcarnitine Profile, Plasma | 070072 | C18 | umol/L | 30560-7 | |
| 070228 | Acylcarnitine Profile, Plasma | 070073 | C18:1 | umol/L | 30542-5 | |
| 070228 | Acylcarnitine Profile, Plasma | 070074 | C18:2 | umol/L | 30534-2 | |
| 070228 | Acylcarnitine Profile, Plasma | 070075 | C18-Hydroxy | umol/L | 35656-8 | |
| 070228 | Acylcarnitine Profile, Plasma | 070076 | C18:1-Hydroxy | umol/L | 30312-3 | |
| 070228 | Acylcarnitine Profile, Plasma | 070077 | C18:2-Hydroxy | umol/L | 30237-2 | |
| 070228 | Acylcarnitine Profile, Plasma | 070082 | Interpretation | 46252-3 | ||
| 070228 | Acylcarnitine Profile, Plasma | 070079 | Director Review | 72486-4 | ||
| 070228 | Acylcarnitine Profile, Plasma | 070080 | Methodology | 49549-9 | ||
| 070228 | Acylcarnitine Profile, Plasma | 700471 | Disclaimer: | N/A |
© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf